RxSight, Inc. RXST
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing high-quality customized vision to patients following cataract surgery. Our proprietary RxSight® Light Adjustable Lens system ("RxSight system") is the first and only commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system is comprised of our RxSight Light Adjustable Lens®(LAL®/LAL+®, collectively the "LAL"), RxSight Light Delivery Device ("LDD") and related accessories. The LAL is a premium intraocular lens ("IOL") made from the proprietary silicone-based photosensitive material that undergoes controlled changes in refractive power when exposed to specific ultraviolet ("UV") light patterns generated by the LDD.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M | $14.7M | — |
| Cost of revenue | $31.5M | $41.0M | $35.3M | $27.7M | $18.1M | $13.0M | — |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M | $1.7M | — |
| R&D | $38.5M | $34.4M | $29.1M | $26.0M | $24.5M | $21.9M | — |
| SG&A | $112.7M | $101.4M | $74.8M | $58.7M | $32.8M | $15.2M | — |
| Total operating expenses | $151.2M | $135.8M | $103.8M | $84.6M | $57.3M | $37.1M | — |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | -$52.8M | -$35.4M | — |
| Interest expense | $19.0K | $21.0K | $3.3M | $4.9M | $3.7M | $510.0K | — |
| Pre-tax income | -$38.9M | -$27.4M | -$48.6M | -$66.7M | -$48.7M | $27.6M | — |
| Income tax | $66.0K | $50.0K | $20.0K | $9.0K | $8.0K | $57.0K | — |
| Net income | -$39 | -$28 | -$49 | -$67 | -$48.7M | $27.6M | — |
| EPS, basic | -0.95 | -0.71 | -1.41 | -2.41 | -3.57 | 0.91 | — |
| EPS, diluted | -0.95 | -0.71 | -1.41 | -2.41 | -3.57 | 0.15 | — |
| Shares, diluted (wtd. avg.) | $40.9M | $38.9M | $34.5M | $27.7M | $13.6M | $5.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $19.9M | $16.7M | $10.4M | $12.6M | $25.2M | $14.5M | $8.8M |
| Short-term investments | $208.2M | $220.5M | $117.5M | $94.0M | $135.0M | $55.0M | — |
| Receivables | $23.4M | $30.1M | $20.3M | $11.0M | $4.9M | $2.9M | — |
| Inventory | $31.6M | $22.0M | $17.4M | $14.8M | $8.0M | $8.3M | — |
| Total current assets | $287.5M | $293.8M | $168.4M | $134.6M | $176.3M | $81.5M | — |
| Property, plant and equipment | $13.1M | $12.4M | $10.8M | $10.1M | $11.2M | $13.3M | — |
| Total assets | $311.8M | $318.6M | $182.6M | $150.2M | $192.7M | $100.7M | — |
| Accounts payable | $5.3M | $4.5M | $3.9M | $2.6M | $1.7M | $1.1M | — |
| Total current liabilities | $26.3M | $25.9M | $20.9M | $17.2M | $11.1M | $11.6M | — |
| Long-term debt | — | — | $0 | $40.2M | $39.8M | $24.4M | — |
| Total liabilities | $36.1M | $37.3M | $22.2M | $60.3M | $54.5M | $44.9M | — |
| Retained earnings | -$661.0M | -$622.1M | -$594.6M | -$546.0M | -$479.3M | -$430.6M | — |
| Total equity | $275.7M | $281.2M | $160.4M | $89.9M | $138.2M | -$430.6M | -$419.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$15.5M | -$16.9M | -$41.6M | -$58.9M | -$44.7M | -$35.2M | — |
| Depreciation and amortisation | $3.3M | $3.6M | $4.1M | $3.9M | $4.0M | $3.9M | — |
| Stock-based compensation | $31.6M | $24.6M | $15.7M | $11.4M | $7.6M | $4.2M | — |
| Capital expenditure | $3.8M | $5.4M | $4.8M | $2.4M | $1.9M | $2.5M | — |
| Investing cash flow | $16.9M | -$99.3M | -$22.1M | $40.0M | -$81.9M | $15.6M | — |
| Financing cash flow | $1.9M | $123.3M | $61.5M | $6.3M | $137.3M | $25.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-187240.
Others in SIC 3851
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| COO | COOPER COMPANIES, INC. | $13.57B | 37.2x | 5.1% |
| BLCO | Bausch & Lomb Corp | $6.44B | — | 6.5% |
| WRBY | Warby Parker Inc. | $3.02B | 2,435.0x | 13.0% |
| EYE | National Vision Holdings, Inc. | $1.32B | 45.2x | 9.0% |
| STAA | STAAR SURGICAL CO | $1.18B | — | -23.7% |
| LUCYW | Innovative Eyewear Inc | $275.5K | — | 62.6% |
| ALC | ALCON INC | — | — | 4.9% |